User:Sayula: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
{{Infobox company |
{{Infobox company |
||
| company_name = Index Ventures |
| company_name = Index Ventures |
||
| company_logo = [[Image:Index Ventures logo.png|200px|Index Ventures logo]] |
| company_logo = [[:Image:Index Ventures logo.png|200px|Index Ventures logo]]<!--Non free file removed by DASHBot--> |
||
| company_type = [[Private Company|Private]] |
| company_type = [[Private Company|Private]] |
||
| foundation = 1996 |
| foundation = 1996 |
||
Revision as of 05:02, 15 February 2011
| 200px|Index Ventures logo | |
| Company type | Private |
|---|---|
| Industry | Private equity |
| Founded | 1996 |
| Headquarters | Geneva, Switzerland |
| Products | Venture capital, Growth capital |
| Total assets | €1.5 billion |
Number of employees | 25+ |
| Website | www.indexventures.com |
Dr Kevin Johnson
Dr. Kevin Johnson (born in Holyhead, Wales on 30th August 1960) is a Partner at Index Ventures life sciences practice and works out of the London office. Kevin joined the venture capital firm in 2010 with a focus on new assets in the biologics area, which will enable the firm to build companies based on the asset-centric model he and Index pioneered.
Since 2004, Kevin worked with Index Ventures Life Sciences team as a venture advisor. Prior to his return to Index he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio companies.
From 1994 onwards, Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research and in 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development, including the first such drug, Humira™ to reach the market. He was also part of the management team that floated CAT on the London Stock Exchange (main market).
Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.
Index Ventures portfolio company involvement
– PanGenetics (Abbott Pharmaceuticals)
– Diartis
Feature Articles
Index appoints Johnson partner - Scrip
Related Awards
In 2010, Pangenetics was shortlisted for the Newsflow category at Genesis 2010 Awards and for a Scrip Award.